Application for quotation of securities - TLX

Oct 4, 2026 at 5:22 PM EDT · Issued by Telix Pharmaceuticals Limited via ASX

Filed with ASX · Oct 4, 2026 at 5:22 PM EDT

On 6ix: 6ix.com/news/application-for-quotation-of-securities-tlx-1

Appendix 2A - Application for quotation of securitiesAppendix 2A - Application for quotation of securities1 / 6Announcement SummaryEntity nameTELIX PHARMACEUTICALS LIMITEDAnnouncement TypeNew announcementDate of this announcementMonday October 05, 2026The +securities to be quoted are:Total number...

View Attachment

6ix hasn’t read this filing yet.

Telix Pharmaceuticals Limited on 6ix

Earlier from Telix Pharmaceuticals

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer ImagingSep 29
FDA Fast Track for BiPASS Pre Biopsy Prostate ImagingSep 29
Change in substantial holdingSep 25
Appendix 3Y Change in Director Interest-D GillSep 25
Grant of waivers of Listing Rule 7.3.4Sep 21

Later from Telix Pharmaceuticals

Notification regarding unquoted securities - TLXOct 4
Notification of cessation of securities - TLXOct 4
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)Oct 6
Telix to Host Capital Markets Day in Melbourne on November 4, 2026Oct 9
Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANMOct 14

All Telix Pharmaceuticals news releases

Follow Telix Pharmaceuticals into a list and get an email when it puts out news.

Follow Telix Pharmaceuticals